<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755963</url>
  </required_header>
  <id_info>
    <org_study_id>PM-20070724</org_study_id>
    <secondary_id>EudraCT: 2007-005685-12</secondary_id>
    <secondary_id>EC 593/2007</secondary_id>
    <nct_id>NCT00755963</nct_id>
  </id_info>
  <brief_title>Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women</brief_title>
  <official_title>The Influence of Hormone Replacement Therapy on the Cerebral Serotonin-1A Receptor Distribution and Mood in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Menopausal and postmenopausal women compose almost 20% of the Austrian population. Two thirds&#xD;
      of all austrian women suffering from depression or anxiety disorders are over 45 years old.&#xD;
      The serotonergic system, partially regulated by the steroid hormones estrogen and&#xD;
      progesterone, plays a major role in the pathogenesis and treatment of these illnesses. To&#xD;
      examine the effect of the hormone replacement therapy on the serotonergic system, twenty-four&#xD;
      postmenopausal women will be measured using positron emission tomography (PET). The&#xD;
      volunteers will participate in two PET scans. The first PET scan will be performed right&#xD;
      before the hormone treatment starts, the second PET scan about 8 weeks after daily treatment&#xD;
      with (1) a combination of estrogen and progesterone or (2) estrogen and placebo. This imaging&#xD;
      study hypothesizes that the expression of the main inhibiting serotonergic receptor (the&#xD;
      serotonin-1A receptor) will be altered by the hormone therapy. The results of the study might&#xD;
      lead to new strategies in the treatment of psychiatric illnesses during and after the&#xD;
      menopausal transition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotonin-1A receptor binding potential</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hormone Replacement</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol valerate</intervention_name>
    <description>Progynova® 21; 2mg/d</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized progesterone</intervention_name>
    <description>Utrogestan®; 200mg/d</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>maltodextrin</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Postmenopausal females (over 14 months of amenorrhoea)&#xD;
&#xD;
          -  Age 50 - 65 years&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Consent not to participate in PET or SPECT studies with an added equivalence dose of&#xD;
             over 15 mSv within 10 years following the final assessment of the participant in this&#xD;
             study&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Steroid hormone treatment within 6 months prior to the inclusion&#xD;
&#xD;
          -  Current substance abuse&#xD;
&#xD;
          -  History of any malign illness&#xD;
&#xD;
          -  Any implant or stainless steel graft&#xD;
&#xD;
          -  Concomitant neurological illness&#xD;
&#xD;
          -  Concomitant psychiatric disorder except anxiety disorders or depression&#xD;
&#xD;
          -  Treatment with a psychotropic agent targeting serotonin-1A and serotonin-2A receptors&#xD;
             or the serotonin transporter such as buspirone, pindolol or SSRIs&#xD;
&#xD;
          -  Clinically relevant abnormalities in the general physical examination and the routine&#xD;
             laboratory screening&#xD;
&#xD;
          -  Concomitant major illness, especially: liver disease, disorders of the endocrine&#xD;
             system, osteoporosis (when treated with vitamine D), any clinically relevant vascular&#xD;
             or heart diseases&#xD;
&#xD;
          -  One of the following gynaecological diseases: ovariectomy, hysterectomy,&#xD;
             endometriosis, cervical smear test: PAP &gt; II&#xD;
&#xD;
          -  Failures to comply with the study protocol or to follow the instructions of the&#xD;
             investigating team&#xD;
&#xD;
          -  Investigations using PET or SPECT within 10 years prior to the inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siegfried Kasper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dept. of Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Dept. of Psychiatry and Psychotherapy</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>ao. Univ.-Prof. Dr. DDr.h.c. Siegfried Kasper</name_title>
    <organization>Department of Psychiatry and Psychotherapy, Medical University of Vienna</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

